Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Accumulated Expenses (2016 - 2026)

Organogenesis Holdings has reported Accumulated Expenses over the past 11 years, most recently at $49.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 25.55% year-over-year to $49.5 million; the TTM value through Dec 2025 reached $49.5 million, up 25.55%, while the annual FY2025 figure was $49.5 million, 25.55% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $49.5 million at Organogenesis Holdings, up from $40.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $49.5 million in Q4 2025 and troughed at $25.4 million in Q1 2021.
  • A 5-year average of $34.0 million and a median of $34.6 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 55.55% in 2021 and later plummeted 30.69% in 2025.
  • Year by year, Accumulated Expenses stood at $37.3 million in 2021, then decreased by 29.08% to $26.4 million in 2022, then grew by 13.71% to $30.1 million in 2023, then surged by 31.19% to $39.5 million in 2024, then grew by 25.55% to $49.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for ORGO at $49.5 million in Q4 2025, $40.3 million in Q3 2025, and $26.3 million in Q2 2025.